Pasireotide as first line medical therapy for selected patients with acromegaly
Authors' conclusion
This series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.
Study context
- Population
- Patients with acromegaly anticipated to be resistant to first-generation somatostatin receptor ligands (SRLs): large, hyperintense tumours on T2-weighted MRI and sparse granulation pattern by histology
- Participants
- 6 patients
- Outcome
- Efficacy of pasireotide
- Follow-up
- Three to eight months
Main finding
As reported in the abstract
- Tumour volume reduced in all patients
- Growth hormone (GH) and IGF-1 levels improved
- Visual field defects normalised
Observational data: associations, not effects.
Safety
- Hyperglycaemia requiring antidiabetic treatment
- 2 patients
Original publication
Pasireotide as first line medical therapy for selected patients with acromegaly. Pituitary. Published 11 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →